Literature DB >> 7927989

Monoclonal immunoglobulin deposition disease: a review of immunoglobulin chain alterations.

J L Preud'homme1, P Aucouturier, G Touchard, A A Khamlichi, A Rocca, L Denoroy, M Cogné.   

Abstract

Monoclonal immunoglobulin deposition disease, a complication of overtly malignant or apparently benign immunoproliferative disorders, is a severe disease featuring tissue deposition of monoclonal light, light and heavy, or heavy chains. A number of converging arguments strongly suggest a direct pathogenetic role of structural abnormalities or peculiarities of variables regions of light and/or heavy chains (associated with deletions in the constant region for the heavy chains). Recent structural data on these abnormal immunoglobulin chains are reviewed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927989     DOI: 10.1016/0192-0561(94)90032-9

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  3 in total

Review 1.  Animal models of monoclonal immunoglobulin-related renal diseases.

Authors:  Christophe Sirac; Guillermo A Herrera; Paul W Sanders; Vecihi Batuman; Sebastien Bender; Maria V Ayala; Vincent Javaugue; Jiamin Teng; Elba A Turbat-Herrera; Michel Cogné; Guy Touchard; Nelson Leung; Frank Bridoux
Journal:  Nat Rev Nephrol       Date:  2018-02-19       Impact factor: 28.314

2.  Complete primary sequences of two lambda immunoglobulin light chains in myelomas with nonamyloid (Randall-type) light chain deposition disease.

Authors:  C Decourt; G Touchard; J L Preud'homme; R Vidal; H Beaufils; M C Diemert; M Cogné
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

3.  Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and "aggregoma": an update on classification and diagnosis.

Authors:  Marco Skardelly; Georgios Pantazis; Sotirios Bisdas; Guenther C Feigl; Martin U Schuhmann; Marcos S Tatagiba; Rainer Ritz
Journal:  BMC Neurol       Date:  2013-08-15       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.